浙江九洲药物科技有限公司
- Country
- Ownership
- -
- Established
- 2006-02-23
- Employees
- -
- Market Cap
- -
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
12
NMPA:12
Drug Approvals
Venlafaxine Hydrochloride Sustained-Release Capsules
- Product Name
- 盐酸文拉法辛缓释胶囊
- Approval Number
- 国药准字H20249314
- Approval Date
- Nov 15, 2024
NMPA
Sitagliptin Phosphate and Metformin Hydrochloride Tablets(Ⅱ)
- Product Name
- 西格列汀二甲双胍片(Ⅱ)
- Approval Number
- 国药准字H20243400
- Approval Date
- Mar 29, 2024
NMPA
Gliclazide Modified Release Tablets
- Product Name
- 格列齐特缓释片
- Approval Number
- 国药准字H20233775
- Approval Date
- Jun 21, 2023
NMPA
Carbamazepine sustained-release tablets（Ⅱ）
- Product Name
- 卡马西平缓释片(Ⅱ)
- Approval Number
- 国药准字H20233650
- Approval Date
- Jun 7, 2023
NMPA
Carbamazepine sustained-release tablets（Ⅱ）
- Product Name
- 卡马西平缓释片(Ⅱ)
- Approval Number
- 国药准字H20233648
- Approval Date
- Jun 7, 2023
NMPA
Carbamazepine sustained-release tablets（Ⅱ）
- Product Name
- 卡马西平缓释片(Ⅱ)
- Approval Number
- 国药准字H20233649
- Approval Date
- Jun 7, 2023
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
No trials found
News
No news found